NCT07594379 Bronchoscopic Airway Clearance for Improving Lung Aeration in Mechanically Ventilated Patients With Atelectasis
| NCT ID | NCT07594379 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Southeast University, China |
| Condition | Atelectasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 104 participants |
| Start Date | 2026-08-05 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 104 participants in total. It began in 2026-08-05 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn whether bedside flexible bronchoscopy-guided airway clearance can improve lung aeration in adult patients who are receiving invasive mechanical ventilation and have atelectasis with a high airway secretion burden. The main questions it aims to answer are: Does bedside flexible bronchoscopy-guided airway clearance reduce the proportion of nonaerated lung tissue from baseline to day 5? Does this treatment improve other lung aeration measures, respiratory mechanics, arterial blood gas parameters, pulmonary infection score, ventilator-free days, intensive care unit length of stay, and safety outcomes? Researchers will compare usual airway care plus bedside flexible bronchoscopy-guided airway clearance with usual airway care alone to see if bronchoscopy-guided airway clearance improves lung aeration and clinical outcomes. Participants will be randomly assigned to one of two groups. Participants in the usual care group will receive standard airway management, which may include airway suctioning, postural drainage, humidification, chest physiotherapy, and other routine respiratory care. Participants in the bronchoscopy group will receive the same usual care, plus bedside flexible bronchoscopy-guided airway clearance when predefined criteria for high airway secretion burden are met. Participants will have clinical assessments during the study, including chest imaging, respiratory mechanics measurements, arterial blood gas tests, pulmonary infection score assessment, and safety monitoring. The main assessment will compare quantitative chest computed tomography findings at baseline and day 5 to evaluate changes in nonaerated lung tissue.
Eligibility Criteria
Inclusion Criteria: 1. Age 18 years or older 2. Receiving invasive mechanical ventilation for at least 48 hours 3. Presence of atelectasis confirmed by chest computed tomography, chest X-ray, or lung ultrasound 4. High airway secretion burden, defined as requiring airway suctioning at least twice per hour during the previous 8 hours 5. Written informed consent obtained from the participant or legally authorized representative Exclusion Criteria: 1. Expected duration of artificial airway maintenance less than 5 days 2. Untreated tension pneumothorax 3. Large pleural effusions requiring thoracentesis. 4. Known or suspected aspiration 5. Active intrapulmonary hemorrhage 6. Severe dysfunction of other organs with expected short-term mortality within 7 days or need for palliative care 7. Any other condition judged by the medical team to make the participant unsuitable for the study 8. Informed consent not obtained
Contact & Investigator
Ling Liu, PHD
PRINCIPAL INVESTIGATOR
Zhongda Hospital, School of Medicine, Southeast University
Frequently Asked Questions
Who can join the NCT07594379 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atelectasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07594379 currently recruiting?
Yes, NCT07594379 is actively recruiting participants. Contact the research team at Smy0116tu@163.com for enrollment information.
Where is the NCT07594379 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT07594379 clinical trial?
NCT07594379 is sponsored by Southeast University, China. The principal investigator is Ling Liu, PHD at Zhongda Hospital, School of Medicine, Southeast University. The trial plans to enroll 104 participants.